drugset
Drugs / Lenzilumab
last change Apr 2023 re-read 9 days ago

Lenzilumab

also known as KB003

Monoclonal antibody targets CSF2 via inhibition

Developed for
COVID-19 · aggressive B-cell non-Hodgkin lymphoma · chronic asthma · chronic myelomonocytic leukemia · rheumatoid arthritis
Investigated by
Humanigen, Inc. · Kite, A Gilead Company · National Institute of Allergy and Infectious Diseases (NIAID) · Peter MacCallum Cancer Centre, Australia

Trials 7

today NCT04534725 · Ph 3 NCT04583969 · Ph 2 NCT04314843 · Ph 1 NCT04351152 · Ph 3 NCT02546284 · Ph 1 NCT01603277 · Ph 2 NCT00995449 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04314843 May 2020 → Mar 2021 aggressive B-cell non-Hodgkin lymphoma Kite, A Gilead Company Terminated No outcome recorded
Phase 1 NCT02546284 Jul 2016 → Feb 2020 chronic myelomonocytic leukemia Humanigen, Inc. Completed No outcome recorded
Phase 23 trials · 2 missed
Phase 2 NCT04583969 Oct 2020 → Apr 2022 COVID-19 National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 2 NCT01603277 Jul 2012 → Jul 2013 chronic asthma Humanigen, Inc. Completed Missed primary
Phase 2 NCT00995449 Jan 2010 → Mar 2011 rheumatoid arthritis Humanigen, Inc. Terminated No outcome recorded
Phase 32 trials · 1 met primary
Phase 3 NCT04534725 Dec 2020 → Nov 2022 COVID-19, cancer, viral respiratory tract infection Peter MacCallum Cancer Centre, Australia Completed Mixed
Phase 3 NCT04351152 May 2020 → Mar 2021 COVID-19 Humanigen, Inc. Unknown Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2019-05-31 Kite, A Gilead Company Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma kitepharma.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Lenzilumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT04534725 ↗
4

NCT02546284 ↗

NCT04583969 ↗

NCT04314843 ↗

NCT04351152 ↗
Known as KB003 “7 intravenous infusions of either 400 mg KB003 or placebo at baseline and weeks 2, 4, 8, 12, 16 and 20.” PMID 26739717 ↗ Jan 2016
1

NCT00995449 ↗
Action Inhibit “Granulocyte-macrophage colony-stimulating factor inhibitor” CHEMBL3707325 ↗
1

“an anti-GM-CSF antibody (KB003)” PMID 26739717 ↗ Jan 2016
Modality Monoclonal antibody “Anti-GM-CSF Monoclonal Antibody” NCT00995449 ↗
Route Intravenous “KB003 IV x5 doses” NCT00995449 ↗
Target CSF2 “Granulocyte-macrophage colony-stimulating factor inhibitor” CHEMBL3707325 ↗